AUM BioTech

Executive Summary

AUM BioTech is a Philadelphia-based pre-clinical biotechnology company pioneering a self-delivering antisense oligonucleotide (sdASO) platform for RNA silencing. Unlike conventional ASOs that require transfection reagents, AUM's sdASOs achieve efficient gene knockdown in vitro and in vivo without additional delivery agents, addressing a key pain point in nucleic acid therapeutics. The platform targets mRNA, miRNA, lncRNA, and viral RNA, positioning it for broad applications in gene regulation and functional genomics. Currently serving the research market, AUM aims to expand into therapeutic development, though it has not yet disclosed any lead programs or financing rounds. The company's innovative delivery technology offers potential advantages in efficacy and ease of use, but its early stage and lack of disclosed pipeline data introduce significant uncertainty.

Upcoming Catalysts (preview)

• Q3 2026Publication of in vivo efficacy data for a lead sdASO program50% success
• Q4 2026Strategic partnership with a larger biotech or pharma for platform licensing40% success
• Q1 2027Series B financing to advance proprietary pipeline into IND-enabling studies45% success